March 25, 2015
BioDot is pleased to announce that the United States Patent and Trademark Office (USPTO) recently awarded a 3rd U.S. patent to BioDot for its FISHArray™ technology and methods. BioDot’s patent family, which includes U.S. Patent No. 8,940,478, U.S. Patent. No. 7,754,439, and U.S. Patent No. 8,323,882, along with additional pending U.S. and foreign applications, broadly covers technology and methods for performing multiple FISH, IHC, and cytogenetic tests on a single substrate, whether performed manually or through automated workstations, such as BioDot’s CellWriter™.
“FISH and Karyotyping assays have historically been performed as a one assay, one slide paradigm. The FISHArray technology and methods show labs that huge economic benefits can be realized through miniaturization and our strong patent portfolio establishes BioDot and its licensed partners as the only authorized suppliers of this technology to the marketplace. We are very proud of the advancements we’ve made in the molecular cytogenetics space and labs licensed to use the patented technology and methods will have a significant advantage over their peers,” said Tom Tisone, CEO of BioDot.
BioDot developed the CellWriter Workstation to enhance the FISHArray technology and methods by automating slide preparation for such a complex assay format. The automation brings additional advantages over the manual method and BioDot is able to help laboratories develop a fully digital workflow through data management and LIS integration.
Tisone added, “Labs also spend millions of dollars on highly sophisticated LIS implementations and CellWriter finally allows them to realize the value of that investment through our automated workflow management. Our patented FISHArray technology and methods are clearly at the core of our value proposition, but we view it as only one side of the story.”
BioDot continues to invest in its technology portfolio and has filed for patents in other application areas within the molecular cytogenetics market. As they lead the way with respect to innovations in the Cytogenetics and Molecular Cytogenetic markets, BioDot looks forward to future announcements for similarly ground breaking technologies.
BioDot is the leading supplier of system tools for the research, development, and commercialization of diagnostic tests. Our mission is to enable, inspire and educate scientists to commercialize their R&D ideas through to manufactured product. Using our core competencies in low volume, non-contact dispensing, BioDot has developed the FISHArray™ technology and methods and the CellWriter™ workstation to streamline the cytogenetics workflow and deliver high throughput automation.With a commitment to fully understanding our customer requirements, BioDot’s personnel have a genuine wish to help you develop your research ideas. Our sales teams are highly trained in providing expert advice in both process and material handling needs. They are backed by a strong support team of application scientists and service engineers.
For More Information Contact:
Brian Kirk, Product Manager – Molecular Diagnostics